[ad_1]
By Chris Wack
The shares of Enochian BioSciences Inc. doubled to $8.97 after the company said the U.S. Food and Drug Administration had accepted a pre-trial request for a new drug for a potential functional cure or treatment for HIV.
The company said written comments are expected this fall.
The stock’s volume was 83 million shares at 12:55 p.m. ET, compared to the 65-day average volume of 258,000 shares. The stock, which has 47.8 million shares outstanding, hit a 52-week high of $12.99 earlier in the session.
Enochian BioSciences said the request was based on the results of a 54-year-old man with HIV who had failed to suppress the virus with antiviral therapy. The patient then achieved viral control for 255 days with an innovative treatment of Natural Killer and Gamma Delta T cells collected from another person.
No antivirals were given during the entire period, the company said. It is believed that the GDT cells, a small subset of immune cells that can be infected with HIV, may be a key factor in controlling the virus.
Enochian BioSciences, which has the exclusive license to the patented technology, said the cellular therapy could be an important approach to achieving a “functional cure” for HIV, potentially allowing individuals with the virus to take the antiviral treatment for longer. stop.
The pre-IND filing requested that the new strategy be extended to include individuals with HIV who suppress the virus with antiviral treatment.
Write Chris Wack at [email protected]
(END) Dow Jones Newswires
June 14, 2021 13:15 ET (17:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
[ad_2]
picture credit